08:04 AM EST, 12/17/2025 (MT Newswires) -- 4D Molecular Therapeutics ( FDMT ) said Wednesday that interim clinical results from its early-stage trial of its 4D-710 genetic medicine for cystic fibrosis, or CF, lung disease demonstrated "clinically meaningful" lung function activity at the 2.5E14 vg dose level.

The study enrolled 16 CF lung disease patients who were either ineligible for or intolerant of CFTR modulator therapies across four dose cohorts: 2E15, 1E15, 5E14, and 2.5E14 vg. Based on safety, efficacy, and tissue expression data, the company selected the 2.5E14 vg dose for mid-stage study, 4DMT said.

4DMT said no new pulmonary or other safety events occurred in the higher-dose cohorts after up to 3.5 years of follow-up. In lower-dose groups with 4 to 24 months of follow-up, treatment-related adverse events were generally mild, transient and resolved by two months, with no severe events reported.

4DMT said it expects to complete mid-stage enrollment in the first half of next year and provide a program update in the second half of next year.